Standard BioTools (NASDAQ:LAB), Inc. (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.
The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling. Standard BioTools also offers real-time PCR arrays, microfluidic access arrays and reagents designed to streamline workflows for target validation, drug discovery and translational research.
Headquartered in South San Francisco, Standard BioTools maintains sales and support operations across North America, Europe and Asia, serving a global customer base of life science researchers and clinicians. The company invests in application development and cross-platform software that enables users to integrate proteomic, genomic and imaging data for deeper biological insights.
In October 2023, the company rebranded from Fluidigm to Standard BioTools to reflect its unified approach to multi-omic and spatial biology solutions. Led by an experienced management team with backgrounds in life sciences innovation and instrumentation, Standard BioTools continues to expand its product portfolio and market reach.
